Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precision Biosciences Inc

5.08
-0.0700-1.36%
Volume:72.48K
Turnover:372.15K
Market Cap:56.33M
PE:-1.82
High:5.21
Open:5.21
Low:5.07
Close:5.15
Loading ...

Precision BioSciences Inc expected to post a loss of $1.57 a share - Earnings Preview

Reuters
·
Yesterday

BRIEF-Precision Biosciences Receives FDA Orphan Drug Designation For Pbgene-Dmd For The Treatment Of Duchenne Muscular Dystrophy

Reuters
·
23 Jul

Precision BioSciences Duchenne muscular dystrophy treatment gets orphan status

TIPRANKS
·
18 Jul

Precision BioSciences announces additional PBGENE-DMD preclinical data

TIPRANKS
·
16 Jul

Precision BioSciences Announces Plans for First-In-Human Clinical Trials of PBGENE-DMD Gene Editing Therapy for Duchenne Muscular Dystrophy in 2025

Reuters
·
16 Jul

Precision BioSciences CFO John Alexander Reports Disposal of Common Shares

Reuters
·
09 Jul

Director Melinda Brown Reports Acquisition of Common Shares in Precision BioSciences Inc

Reuters
·
27 Jun

BRIEF-Precision Biosciences Receives FDA Rare Pediatric Disease

Reuters
·
25 Jun

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for Duchenne Muscular Dystrophy Treatment

Reuters
·
25 Jun

Precision BioSciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
03 Jun

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
21 May

Precision BioSciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Precision BioSciences Reports Sharp Revenue Decline in Q1 2025 with Less Than $0.1M from Previous $17.6M

Reuters
·
15 May

BRIEF-Precision Biosciences Q1 Income From Operations USD -22.112 Million

Reuters
·
15 May

Precision BioSciences Q1 EPS $(2.21) Misses $(1.72) Estimate, Sales $29.00K Miss $5.00M Estimate

Benzinga
·
15 May

Precision BioSciences Announces Acceleration of PBGENE-DMD Gene Editing Approach for Duchenne Muscular Dystrophy

Reuters
·
15 May

Precision BioSciences Inc. Highlights PBGENE-DMD at American Society of Gene and Cell Therapy Annual Meeting

Reuters
·
15 May

Precision BioSciences Inc expected to post a loss of $1.72 a share - Earnings Preview

Reuters
·
10 May

Press Release: Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

Dow Jones
·
08 May

Precision BioSciences Inc. to Present Multiple Gene Editing Programs at ASGCT Annual Meeting

Reuters
·
01 May